Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
about
Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?A focus on intra-abdominal infections.Prospective monitoring of cefepime in intensive care unit adult patientsHistory of antibiotics. From salvarsan to cephalosporins.Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study.Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent OrganismsSHV-129: A Gateway to Global Suppressors in the SHV β-Lactamase Family?Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Intermittent hemodialysis treatment in cefepime-induced neurotoxicity: case report, pharmacokinetic modeling, and review of the literature.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature.Influence of borderline cefepime MIC on the outcome of cefepime-susceptible Pseudomonas aeruginosa bacteremia treated with a maximal cefepime dose: a hospital-based retrospective study.WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.Cefepime and mortality: a real issue?What does the susceptible-dose dependent interpretive category for cefepime in ESBL-producing bacteria?Red man syndrome adverse reaction following intravenous infusion of cefepimeEffect of cefepime dose on mortality of patients with Gram-negative bacterial bloodstream infections: a prospective cohort study.Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.A rapid and simple method to detect ESBL in Enterobacter cloacae based on MIC of cefepime.
P2860
Q33601573-F4B83ED4-0358-4D3F-A2EE-6065CB0B191EQ33763449-E72395F7-73E8-4581-841C-9BE8E940DBE1Q33919165-4E60E48F-000A-436C-AA41-139BEF85D34BQ34262986-A9B41C4A-2A24-4A84-B37D-4E1A4E732D37Q34635418-BA6C3DDA-9BCC-4257-8CE0-791AC34E678DQ36086501-85480385-6ACC-4F54-8CBD-5838E38E03D9Q36290815-21E12C29-A0D7-44F0-A59D-9390B2646F5CQ36730158-62A69865-8EE0-4899-B326-9C1B874F803AQ37007861-6A56631D-BF05-4C31-88B9-89A81CA693A2Q37656243-F804072A-6AEC-4D0C-B459-D56942EB2E72Q38165138-C08C1DBD-2159-439B-8B16-98DF3A0AEA4DQ38232834-ABFFA72D-4A48-4DE6-B9D1-11561DB4A06BQ38650049-7A0C2F0E-C810-4D0C-8E22-AF744F0FF269Q38981397-D72CAD48-B4ED-47D2-A7CC-D895A2D523AAQ40073768-3BF61688-BD73-4E0E-B377-32A13689227FQ40122145-6F912AE1-D7E4-4DBE-8F74-7F5AFF51682CQ40281991-0DC0FE8C-5929-44DD-B41F-1FF77BF25D1CQ40315393-F1806490-A34E-48C9-B047-227D351C29B0Q40352823-E63FE4E3-747B-4FC6-97B3-2225CE816BEEQ40366605-525E79C8-29BB-4704-BF55-F8B7329E4A7DQ40714813-C701AEE5-7EF7-4009-BF14-57B42DCCB7A1Q41183521-5A324808-319C-4573-BC9E-21CFEA334414Q42230747-E6294416-62F0-41E7-8C7C-A99C3E4409C8Q45341557-A69C3C77-D0EE-497B-AC64-31F8252DAF24Q54162166-56E73E5A-72F4-4D71-8694-19014ED7BDE1
P2860
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
@en
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
@nl
type
label
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
@en
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
@nl
prefLabel
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
@en
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
@nl
P2860
P356
P1476
Cefepime: a reappraisal in an era of increasing antimicrobial resistance.
@en
P2093
Andrea Endimiani
Federico Perez
P2860
P304
P356
10.1586/14787210.6.6.805
P577
2008-12-01T00:00:00Z